Progyny (PGNY) Stock Price, News & Analysis

Company Overview

Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.

Key Stats

• Today's Range: $21.49 to $22.14
• 50-Day Range: $19.82 to $23.88
• 52-Week Range: $13.39 to $38.98
• Volume: 1.04 million shs
• Average Volume: 1.62 million shs
• Market Capitalization: $1.84 billion
• P/E Ratio: 37.05
• Dividend Yield: N/A
• Price Target: $24.82
• Consensus Rating: Hold

Progyny Stock Analysis - MarketRank™

Progyny scored higher than 47% of companies evaluated by MarketBeat, and ranked 565th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.2 / 5
• Analyst Rating: Hold

Consensus Rating

Progyny has received a consensus rating of Hold. The company's average rating score is 2.31, and is based on 4 buy ratings, 9 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Progyny has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 8.33%

Earnings Growth

Earnings for Progyny are expected to grow by 8.33% in the coming year, from $0.60 to $0.65 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Progyny is 37.05, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 23.47.

Price to Earnings Ratio vs. Sector

The P/E ratio of Progyny is 37.05, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 24.55.

Price to Earnings Growth Ratio

Progyny has a PEG Ratio of 2.39. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Progyny has a P/B Ratio of 3.72. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

15.93% of the float of Progyny has been sold short.

Short Interest Ratio / Days to Cover

Progyny has a short interest ratio ("days to cover") of 6.

Change versus previous month

Short interest in Progyny has recently decreased by 2.40%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Progyny does not currently pay a dividend.

Dividend Growth

Progyny does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

15.93% of the float of Progyny has been sold short.

Short Interest Ratio / Days to Cover

Progyny has a short interest ratio ("days to cover") of 6.

Change versus previous month

Short interest in Progyny has recently decreased by 2.40%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 1.25

News Sentiment

Progyny has a news sentiment score of 1.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Progyny this week, compared to 7 articles on an average week.

Search Interest

Only 1 people have searched for PGNY on MarketBeat in the last 30 days. This is a decrease of -90% compared to the previous 30 days.

MarketBeat Follows

2 people have added Progyny to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Progyny insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,202,000.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

12.30% of the stock of Progyny is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

94.93% of the stock of Progyny is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PGNY Stock Analysis - Frequently Asked Questions

How have PGNY shares performed this year?

Progyny's stock was trading at $17.25 at the start of the year. Since then, PGNY stock has increased by 24.6% and is now trading at $21.49.
View the best growth stocks for 2025 here.

How were Progyny's earnings last quarter?

Progyny, Inc. (NASDAQ:PGNY) released its quarterly earnings data on Tuesday, November, 12th. The company reported $0.11 earnings per share for the quarter, missing analysts' consensus estimates of $0.37 by $0.26. The firm's revenue was up 2.0% compared to the same quarter last year.

When did Progyny IPO?

Progyny (PGNY) raised $150 million in an initial public offering (IPO) on Friday, October 25th 2019. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Citigroup, Piper Jaffray, SVB Leerink and TPG Capital were co-managers.

Who are Progyny's major shareholders?

Top institutional investors of Progyny include Vanguard Group Inc. (10.21%), Pacer Advisors Inc. (4.32%), T. Rowe Price Investment Management Inc. (3.83%) and Geode Capital Management LLC (2.14%). Insiders that own company stock include Tpg Gp A, Llc, Peter Anevski, Michael E Sturmer, Norman Payson, David J Schlanger, Mark S Livingston, Cheryl Scott and Kevin K Gordon.
View institutional ownership trends.

How do I buy shares of Progyny?

Shares of PGNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Progyny own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Progyny investors own include Humana (HUM), American Water Works (AWK), NVIDIA (NVDA), Rambus (RMBS), Voyager Therapeutics (VYGR), Saia (SAIA) and Waste Connections (WCN).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 3/25/2025
• Next Earnings (Estimated): 5/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Miscellaneous health & allied services, not elsewhere classified
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:PGNY
• CIK: 1551306
• Web: www.progyny.com
• Phone: 212-888-3124
• Fax: N/A
• Employees: 310
• Year Founded: 2008

Price Target and Rating

• Average Stock Price Target: $24.82
• High Stock Price Target: $41.00
• Low Stock Price Target: $17.00
• Potential Upside/Downside: +13.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.31
• Research Coverage: 13 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $0.57
• Trailing P/E Ratio: 37.92
• Forward P/E Ratio: 36.48
• P/E Growth: 2.39
• Net Income: $62.04 million
• Net Margins: 5.03%
• Pretax Margin: 7.18%
• Return on Equity: 11.36%
• Return on Assets: 7.87%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.62
• Quick Ratio: 2.62

Sales & Book Value

• Annual Sales: $1.17 billion
• Price / Sales: 1.60
• Cash Flow: $0.62 per share
• Price / Cash Flow: 35.58
• Book Value: $5.77 per share
• Price / Book: 3.79

Miscellaneous

• Outstanding Shares: 85,413,000
• Free Float: 74,679,000
• Market Cap: $1.87 billion
• Optionable: Optionable
• Beta: 1.41